Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Testicular Neoplasms 2Neoplasms, Germ Cell and Embryonal 2Carcinoma, Embryonal 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Nonseminomatous germ cell tumor 1Neoplasm Metastasis 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 4Etoposide 3pembrolizumab 2fludarabine 2etoposide phosphate 2Sirolimus 2Paclitaxel 2Mesna 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Cisplatin 2Carboplatin 2Busulfan 2Brentuximab Vedotin 2tremelimumab 1ripretinib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1pazopanib 1guadecitabine 1fosaprepitant 1fludarabine phosphate 1durvalumab 1bintrafusp alfa protein, human 1avelumab 1Vorinostat 1Ursodeoxycholic Acid 1Topotecan 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms, Germ Cell and Embryonal × Brentuximab Vedotin × Genitourinary × Clear all
NCT02689219 2019-12-10

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Indiana University

Phase 2 Terminated
18 enrolled 13 charts
Genitourinary

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Carcinoma, Embryonal

NCT01851200 2018-02-07

Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors

Fondazione Michelangelo

Phase 2 Completed
9 enrolled
Genitourinary

Neoplasm Metastasis, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Carcinoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡